7F0 Stock Overview
Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.10 |
| 52 Week High | US$27.15 |
| 52 Week Low | US$15.70 |
| Beta | 1.51 |
| 11 Month Change | -8.52% |
| 3 Month Change | -24.06% |
| 1 Year Change | -34.95% |
| 33 Year Change | -79.21% |
| 5 Year Change | 56.31% |
| Change since IPO | 56.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7F0 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.2% | 0.1% | -0.02% |
| 1Y | -34.9% | 17.2% | 8.2% |
Return vs Industry: 7F0 underperformed the German Healthcare industry which returned 17.2% over the past year.
Return vs Market: 7F0 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 7F0 volatility | |
|---|---|
| 7F0 Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 7F0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7F0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,184 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
| 7F0 fundamental statistics | |
|---|---|
| Market cap | €524.89m |
| Earnings (TTM) | -€158.42m |
| Revenue (TTM) | €266.73m |
2.0x
P/S Ratio-3.3x
P/E RatioIs 7F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7F0 income statement (TTM) | |
|---|---|
| Revenue | US$277.76m |
| Cost of Revenue | US$177.17m |
| Gross Profit | US$100.60m |
| Other Expenses | US$265.56m |
| Earnings | -US$164.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.39 |
| Gross Margin | 36.22% |
| Net Profit Margin | -59.39% |
| Debt/Equity Ratio | 0.3% |
How did 7F0 perform over the long term?
See historical performance and comparison